AbCellera Biologics Inc. (ABCL) vs Abbott Laboratories (ABT)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ABCL | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Devices |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | NYSE |
| Country | Canada | United States |
| Theme | life-science-tools | medical-devices |
| Price and returns | ||
| Last close | $12.08 | $104.88 |
| Return · 1 week | +1.26% | +0.79% |
| Return · 1 month | −13.22% | +3.86% |
| Return · 3 months | +128.36% | −2.23% |
| Return · year to date | +252.19% | −14.59% |
| Return · 1 year | +109.36% | −16.60% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −19.55% | −20.56% |
| 52-week high | $15.02 | $132.03 |
| 52-week low | $2.75 | $81.97 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $3.91B | $182.68B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $59.80M | $816.81M |
| Employees | 562 | 122,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 33.84× |
| Price to earnings · forward | n/a (negative forward earnings) | 17.29× |
| Price to sales | 61.44× | 3.92× |
| Price to book | 4.29× | 3.55× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 17.92× |
| Enterprise value to revenue | 53.34× | 4.49× |
| PEG ratio | — | 1.92 |
| Earnings per share · trailing | -0.54 | 3.10 |
| Profitability | ||
| Gross margin | — | 56.61% |
| Operating margin | −1550.05% | 14.71% |
| Profit margin | −248.84% | 11.59% |
| Return on equity | −17.30% | 10.58% |
| Return on assets | −10.39% | 5.33% |
| Growth | ||
| Revenue growth | −76.30% | +13.00% |
| Earnings growth | — | −47.50% |
| Balance sheet and payout | ||
| Debt / equity (%) | 15.14 | 63.21 |
| Current ratio | 12.77 | 1.38 |
| Dividend yield | 0.00% | 2.40% |
| Payout ratio | 0.00% | 78.71% |
| Trend and volatility | ||
| RSI · 14 | 48.66 | 57.14 |
| ADX · 14 | 14.92 | 20.25 |
| 50-day average | $12.17 | $105.04 |
| 200-day average | $6.68 | $102.11 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 6.43% | 2.75% |
The full ABCL analysis
Everything this table leaves out for AbCellera Biologics Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABCL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABCL analysisThe full ABT analysis
Everything this table leaves out for Abbott Laboratories: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABT argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABT analysis